Clinical Trial

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

Study acronym: FLASH
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is for men with prostate cancer who are experiencing hot flashes due to treatments that lower testosterone. Hot flashes can affect your quality of life and make it harder for patients to continue their treatment, so researchers want to find a better way to manage them. The study is testing a drug called fezolinetant, which might help reduce hot flashes without using hormones. Fezolinetant is a drug that is currently approved for the treatment of hot flashes in menopausal women.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-06; most recent amendment 2026-02-02.
Status change: Not Yet Recruiting → Recruiting 2026-02-02
Trial Details
NCT Number NCT06972875
Lead Sponsor University of Vermont
Conditions Prostate CA, Androgen Deprivation Therapy
Enrollment 32 participants
Start Date 2025-12-18
Primary Completion 2027-01 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-05